Abstract:Interstitial lung disease (ILD) comprises a group of respiratory diseases affecting the interstitium of the lungs, which occur when a lung injury triggers an abnormal healing response, and an inflammatory process leads to altered diffusion and restrictive respiratory dysfunction. The term "interstitial" may be misleading, as other components of the lungs are usually also involved (epithelium, airways, endothelium, and so on). Pediatric conditions (childhood interstitial lung disease, chILD) are different from adult forms, as growing and developing lungs are affected and more diverse and less prevalent diseases are seen in childhood. Diffuse parenchymal lung disease (DPLD) and diffuse lung disease (DLD) can be used interchangeably with ILD. Known etiologies of chILD include chronic infections, bronchopulmonary dysplasia, aspiration, genetic mutations leading to surfactant dysfunction, and hypersensitivity pneumonitis due to drugs or environmental exposures. Many forms are seen in disorders with pulmonary involvement (connective tissue disorders, storage diseases, malignancies, and so on), but several conditions have unknown origins (desquamative pneumonitis, pulmonary interstitial glycogenosis, neuroendocrine cell hyperplasia in infancy, and so on). Currently, there is no consensus on pediatric classification; however, age grouping is proposed as some specific forms are more prevalent in infancy (developmental and growth abnormalities, surfactant dysfunction mutations, etc.) and others are usually seen in older cohorts (disorders in normal or immunocompromised hosts, systemic diseases, etc.). Clinical manifestations vary from mild nonspecific symptoms (recurrent respiratory infections, exercise intolerance, failure to thrive, dry cough, etc.) to a severe clinical picture (respiratory distress) and presentation related to the child's age. The diagnostic approach relies on imaging techniques (CT), but further investigations including genetic tests, BAL, and lung biopsy (VATS) are needed in uncertain cases. Pharmacological treatment is mostly empiric and based on anti-inflammatory and immunomodulatory drugs. Lung transplantation for selected cases in a pediatric transplantation center could be an option; however, limited data and evidence are available regarding long-term survival. International collaboration is warranted to understand chILD entities better and improve the outcomes of these patients.

Children interstitial lung disease: Assessment and management

Approach to the patient with Childhood Interstitial and Diffuse Lung Disease

Clinical Study on Interstitial Lung Disease in Children of China

Pediatric Diffuse Lung Disease in Infants: Imaging Findings and Histopathologic Correlation

Interstitial Lung Disease in Children: High-Resolution CT Findings in 14 Patients

Clinical Characteristics and Genetic Analysis of Interstitial Lung Disease in Chinese Children (Genes and Interstitial Lung Disease)

Childrens interstitial lung disease (chILD): less rare than we thought?

The Clinical Approach to Interstitial Lung Disease in Childhood: A Narrative Review Article

Clinical scope and healthcare utilization in childhood interstitial lung disease at a tertiary center

Innovations in the care of childhood interstitial lung disease associated with connective tissue disease and immune‐mediated disorders

Inflammatory parameters and innate lymphoid cells in chilhood interstitial lung diseases: a prospective study

Pulmonary fibrosis may begin in infancy: from childhood to adult interstitial lung disease

Epidemiology of childhood interstitial lung disease in France: the RespiRare cohort

The diagnostic utility of BAL in children with interstitial lung disease

Clinical Features and Outcomes of Children's Interstitial Lung Disease Accompanied with Connective Tissue Disease: A Prospective Cohort Study.

Three cases report of childhood interstitial lung disease caused by SFTPC mutations with reduced penetrance and genotype-phenotype correlation analysis

Congenital interstitial lung diseases: What the anesthesiologist needs to know

Surfactant protein disorders in childhood interstitial lung disease

[Risk Factors for Pleural Lung Disease in Children with Juvenile Idiopathic Arthritis].

ERS statement on transition of care in childhood interstitial lung diseases

Pulmonary surfactant metabolism dysfunction: A pediatric clinical case report